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ABSTRACT
Background and aims Mutational load (ML) has been
shown to help risk-stratify those that may progress from
non-dysplastic Barrett’s oesophagus (BE) to dysplastic
disease. Management of patients with BE and indefinite
for dysplasia (BE-IND) is challenging and risk stratification
tools are lacking. The aim of this pilot study is to evaluate
the utility of ML for risk stratification in patients with BEIND.
Methods This is a single-centre, retrospective pilot
study evaluating ML quantification in patients with BEIND. Histology at follow-up endoscopy at least 1 year
after the baseline endoscopy was used to determine if a
patient progressed to low or high dysplasia. The ML levels
were then compared among patients who progressed to
dysplasia versus those who did not.
Results Thirty-five patients who met the inclusion criteria
were identified, and seven met the exclusion criteria.
Twenty-eight patients were analysed, of whom eight
progressed to low-grade dysplasia (6) and high-grade
dysplasia (2). Seven of these eight patients had some
level of genomic instability detected in their IND biopsy
(ML ≥0.5). Ten of the 20 (50%) who did not progress
had no ML level. At an ML cut-off above 1.5, the risk of
progression to high-grade dysplasia was 33% vs 0%
(p=0.005), with a sensitivity of 100% and a specificity of
85%.
Conclusion These results indicate that ML may be able to
risk-stratify progression to high-grade dysplasia in BE-IND.
Larger studies are needed to confirm these findings.

Introduction
Barrett’s oesophagus (BE) is defined as a
change from normal oesophageal squamous
epithelium to metaplastic columnar epithelium with goblet cells, usually in association
with gastro-oesophageal reflux disease.1 It is
a major risk factor for oesophageal adenocarcinoma. Despite recommendations for
screening and surveillance in Barrett’s, the
incidence of oesophageal adenocarcinoma
continues to rise.2 It is estimated that 5.6% of
the adult population have BE in the USA.1 The
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Summary box
What is already known about this subject?
►► Mutational load has been shown to help risk-strat-

ify those that may progress from non-dysplastic
Barrett’s oesophagus to dysplastic disease.
►► Management of patients with Barrett’s oesophagus
and indefinite for dysplasia is challenging and risk
stratification tools are lacking.

What are the new findings?
►► This pilot study shows that mutational load may be

able to risk-stratify which patients progress to highgrade dysplasia.

How might it impact on clinical practice in the
foreseeable future?
►► If our results are reproducible in large studies, then

mutational load may be an option to risk-stratify patients with Barrett’s oesophagus and indefinite for
dysplasia.

only currently used biomarker for risk stratification of BE is dysplasia. However finding
and appropriately classifying dysplasia can be
difficult. Often dysplasia is focal and finding
it can be challenging given most sampling
techniques sample a minority of the Barrett’s
mucosa. Dysplasia in BE has been classified
in a three-tier system as follows: indefinite for
dysplasia (IND), low-grade dysplasia (LGD),
and high-grade dysplasia (HGD) .3 4 IND is
a category where the observed architectural
and nuclear abnormalities are less diagnostic
than those seen in clear-cut dysplasia, or
when there are significant architectural/cytological atypical features but also significant
concomitant inflammation such that reactive atypia cannot be excluded. In clinical
practice LGD and IND are often treated the
same way in regard to surveillance.5 However,
with the recent shift in the guidelines to ablation of LGD due to a randomised control
1
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trial showing benefit in regard to lack of progression to
neoplasia, it is a bit unclear clinically how to manage IND
patients.6 7 In addition, a recent multicentre study has
shown that patients diagnosed with IND behave similarly
to LGD in regard to biological behaviour.5 Triaging IND
patients according to risk of future progression would
help to limit unnecessary repeat endoscopies in patients
at low risk and justify closer observation in patients at
higher risk, perhaps even supporting early means of
cancer prevention such as ablation.
Thus, other biomarkers may be helpful in risk stratification in BE-IND. Currently, dysplasia is the only biomarker
used to risk-stratify BE. Despite its widespread use, it is
unclear whether surveillance endoscopy to detect this
biomarker is useful.8–11 As a result research for other
biomarkers, particularly molecular biomarkers, to help
risk-stratify BE is under way.12–15 One potential biomarker
that has been identified is mutational load (ML) as
a measure of genetic aberration and instability.16 ML
provides a measure of cumulative genomic instability at
10 key genomic loci in patients with BE by assessing DNA
damage in proximity to tumour suppressor genes associated with progression to HGD and EA. BE tissue with
a higher degree of genetic aberrations, specifically loss
of heterozygosity (LOH) of tumour suppressor genes,
progresses to more advanced disease.17
ML assessment can be determined using a commercially available test (BarreGEN, Interpace Diagnostics,
Pittsburgh, Pennsylvania, USA). The test quantifies the
degree of cumulative genetic derangement of 10 genetic
loci of tumour suppressor genes, specifically assessing
the presence of LOH mutations and new alleles consistent with microsatellite instability (MSI). The following
genetic loci are tested, with their tumour suppressor
genes in parentheses: 1p (CMM1, L-myc), 3p (VHL,
HoGG1), 5q (MCC, APC), 9p (CDKN2A), 10q (PTEN,
MXI1), 17p (TP53), 17q (RNF43, NME1), 18q (SMAD4,
DCC), 21q (TFF1, PSEN2) and 22q (NF2).16 18 All LOH
mutations are assigned a numerical value based on the
degree of derangement. ML consists of a statistically
derived weighted scoring system from 0 to 10, with 0
representing the lowest level of genomic instability and 10
representing the highest level of genomic instability.16 19
A recent case–control study evaluated the utility of ML
in predicting progression to neoplasia (HGD or intramucosal cancer) based on samples of only BE with LGD or
non-dysplastic BE at baseline.16 Cases that progressed to
neoplasia on follow-up (23 patients) were compared with
controls (46 patients who did not progress to neoplasia).
The mean ML was higher in cases that progressed than
controls (2.21 vs 0.42, p<0.001). The study concluded
that ML in preprogression tissue can predict progression to neoplasia in BE and thus may serve as a useful
biomarker in surveillance of BE.
ML is proportional to the degree of dysplasia, and thus
may serve as an adjunctive test in patients with equivocal
histology. A retrospective study looked at 271 patients
with varying degrees of dysplasia (IND, LGD and HGD).18
2

The authors found that the ML correlated to the grade of
dysplasia (1.1 vs 2.2 vs 3.3, respectively; correlation coefficient=0.60, p<0.0001). The authors concluded that ML
may be a useful adjunct to histological evaluation. Another
retrospective study examined 877 microdissected targets
from BE biopsies. Increasing ML correlated to increasing
severe histology in regard to grade of dysplasia (correlation coefficient=0.68, p<0.0001).19
The aim of this study is to determine if ML can help
risk-stratify patients with BE-IND.

Methods
This is a retrospective review of patients diagnosed with
BE-IND at North Shore University Hospital from 2013 to
2017. A prospectively maintained database was searched
for consecutive patients. The inclusion criteria included
(1) diagnosis of BE-IND on an endoscopic exam without
a concurrent diagnosis of true dysplasia elsewhere in
the oesophagus; (2) underwent endoscopic surveillance
for IND with Seattle protocol biopsies20; (3) underwent
ML testing for risk stratification on the index endoscopy
biopsies showing IND (preprogression tissue); and (4)
had adequate follow-up of at least 1 year if no dysplasia
was detected on subsequent exams. Exclusion criteria
included the following: (1) underwent endoscopic ablation; (2) lack of 1-year follow-up for patients who did not
have dysplasia on a follow-up exam; (3) history of LGD or
HGD; (4) dysplasia developing within 1 year of the initial
endoscopy (as the dysplasia was likely present on the
index exam); (5) presence of oesophagitis on histology
or endoscopy; and (6) patient not on a medical antacid
regimen.
ML testing was performed on baseline IND biopsy
tissue blinded to the future progression status of patients
(BarreGEN, Interpace Diagnostics). All cases in this series
were re-examined by the pathologist and only targets that
contained the IND were used. ML was measured using
the formalin-fixed, paraffin-embedded (FFPE) tissue
from biopsies taken at the time of baseline endoscopy.
H&E-stained FFPE slides were microscopically examined
by pathologists to identify representative areas of IND
histology. H&E-stained slides were used to guide microdissection of recut, unstained, 4 μm thick, FFPE slides.
Slides were microdissected for the maximum number of
histological targets with IND available for each patient.
Microdissection was performed manually, targeting areas
in which epithelial cells constituted 90% or more of the
total cells removed. By microscopic estimation, no more
than 10% of microdissected cells were stromal or inflammatory cells. Accuracy of all microdissections was carefully reviewed by two pathologists.
Selected areas for microdissection contained mainly
epithelial cells. DNA from the microdissected targets
was then prepared. PCR and quantitative capillary electrophoresis of DNA were used to detect the presence of
LOH and new alleles consistent with MSI of the selected
DNA markers for the previously discussed 10 genetic loci
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of tumour suppressor genes. For each microdissected
tissue, it was determined whether each LOH mutation is
of low (50%–75% of the DNA contained LOH) or high
(>75% of the DNA contains LOH mutations) clonality.
The sum of the clonality of each genetic loci is the ML.19
Two gastrointestinal pathologists (GL and RMT), with
extensive experience in a high-volume Barrett’s tertiary
care referral centre, reviewed all initial IND histology
and follow-up histology. For the purposes of this study,
the histology was rereviewed to ensure IND was an accurate diagnosis prior to preparation for ML analysis. This
rereview also served to help locate the area on the tissue
where ML would be measured. It should be noted that
in our institution, the current clinical practice is that
any diagnosis of dysplasia including IND is reviewed at
the gastrointestinal pathology consensus meeting, where
three to five gastrointestinal pathologists are present.
Patient characteristics were abstracted from the
medical chart. Data analysis was separated into two
groups. The first group was subjects with BE and IND
on the index endoscopy who developed dysplasia (LGD,
HGD or intramucosal cancer) on subsequent follow-up
at least 1 year after the index pathology of IND. The
second group was subjects with BE and IND on the index
endoscopy who did not develop dysplasia on subsequent
follow-up at least 1 year after the index pathology of IND.
These patients had non-dysplastic histology or continued
IND histology on follow-up exams. The two groups were
compared to determine if there is an ML cut-off that can
predict progression to dysplasia or neoplasia (HGD/
intramucosal cancer) in the IND cohort within 1 year of
the index endoscopy.
χ2 and Fisher’s exact tests were used to compare categorical variables, and the Student’s t-test was used for
continuous variables. All analyses were conducted using
SAS V.9.4.

analysed 28 consecutive IND patients at baseline biopsy,
61% were male with a mean age of 64 years (table 1).
All IND pathology was confirmed by the pathologists in
this study without disagreement. All patients had 1-year
follow-up endoscopy, with corresponding follow-up
biopsy indicating no progression or indicating progression to LGD or HGD, with 22 patients (79%) having 2
years and 15 patients (54%) having 3 years of endoscopic
surveillance follow-up. Of all IND patients, six eventually
progressed to LGD (21%) and two to HGD (7%). The
baseline mean BE segment length was similar in IND
patients who later progressed to LGD (4.0 cm) versus
those who did not (3.7 cm), but significantly longer in
patients who progressed to HGD (7.5 cm). Of all patients
with baseline IND, 29% (8/28) progressed to LGD or
HGD, while only 7% (2/28) progressed to HGD.
For analysis, ML scores in IND biopsies were grouped
into numerical categories shown in tables 2 and 3.
Many IND patients who did not progress to LGD or
HGD lacked all detectable genomic instability (10/20)
(ML=0; table 2). By contrast 88% (7/8) of patients who
progressed to LGD or HGD had at least some level of
genomic instability detected in their IND biopsy (ML
≥0.5). The sensitivity and specificity for identifying
patients who would later progress to LGD or HGD at this
ML threshold were 88% and 50%, respectively (table 2).
Using this ML threshold for genomic instability (ML
≥0.5) separated patients who had an initial 29% risk of
progression to LGD or HGD at baseline into two, more
refined risk categories: (1) those at lower risk of progression to LGD or HGD (9% risk of progression) and (2)
those at higher risk of progression to LGD or HGD (41%
risk of progression) (9% vs 41%, p=0.07). Higher levels
of genomic instability provided higher specificity for
predicting which IND patients would progress but at the
expense of lower sensitivity for progression.
In contrast, patients who progressed to HGD had
comparably higher levels of genomic instability at
baseline IND biopsy (ML ≥1.5; table 3). The sensitivity
and specificity for identifying patients who would later
progress to HGD at this ML threshold were 100% and
85%, respectively. Using this ML threshold for genomic

Results
Thirty-five patients who met the inclusion criteria were
identified, and seven who met the exclusion criteria were
excluded (three with oesophagitis, three without 1-year
follow-up and one not on antacid medication). The study
Table 1 Patient demographics
IND progressed to
HGD
n=2

IND progressed to
LGD
n=6

No IND
progression
n=20

All IND
n=28

Age (years), mean
Sex (male)

57
2/2 (100%)

61.17
5/6 (83.33%)

65.2
10/20 (50%)

63.75
17/28 (60.71 %)

Hiatal hernia

1/2 (50%)

1/6 (16.67%)

7/20 (35%)

9/28 (32.14%)

Length mean (cm)

7.5

4

3.68

4.04

Patients had 1-year follow-up exam

2/2 (100%)

6/6 (100%)

20/20 (100%)

28/28 (100%)

2-year follow-up
3-year follow-up

2/2 (100%)
2/2 (100%)

4/6 (66.67%)
2/6 (33.33%)

16/20 (80%)
11/20 (55%)

22/28 (78.57%)
15/28 (53.57%)

HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia.
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Table 2 ML performance in predicting future progression to LGD or HGD in IND patients at baseline

ML=0
ML=0.5–0.75

No IND progression IND progressed to Specificity
LGD or HGD
LGD or HGD
(%)

Sensitivity
(%)

% IND that progressed to LGD
or HGD

10

1

NA

NA

3

3

50

88

9% of IND progressed
(lower risk)
41% of IND progressed
(higher risk)

ML=1.0–1.25

4

1

65

50

ML=1.5–1.75

2

1

85

38

1
20

2
8

95

25

ML ≥2
Total

Overall 29% of IND progressed

HGD, high-grade dysplasia; IND, indefinite for dysplasia; LGD, low-grade dysplasia; ML, mutational load; NA, not available.

instability (ML ≥1.5) separated patients who had an
initial 7% risk of progression to HGD at baseline into
two, more refined risk categories: (1) those at lower risk
of progression to HGD (0% rate of progression) and (2)
those at higher risk of progression to HGD (33% rate of
progression) (0% vs 33%, p=0.005). Again, higher levels
of genomic instability provided higher specificity for
predicting which IND patients would progress to HGD.

abnormalities from FFPE tissue, such as aneuploidy
measured by flow cytometry, in predicting progression
from IND to dysplasia.23 24 These studies show that DNA
flow cytometry can risk-stratify patients with BE-IND who
will progress to dysplasia.
Our results show that patients with an ML above 0.5
should be considered for more frequent surveillance
compared with those with no ML, as these patients had
a higher risk of progression to low-grade and high-grade
dysplasia (41% vs 9%, p<0.07). The result was not significant likely due to the small sample size. On the other
hand, an ML above 1.5 statistically predicted progression to HGD versus those with an ML below 1.5 (33%
vs 0%, p=0.005). Based on this, an ML above 1.5 should
be strongly considered for frequent surveillance and
perhaps even advanced imaging if no obvious lesions are
visualised given the focal nature of dysplasia.
Not surprisingly, our results are more robust for risk
stratification in regard to patients who eventually develop
HGD compared with those patients who progressed to
LGD. This could be related to the inherent issues with
the classification of LGD,25–27 which include high interobserver variability among expert pathologists. A sensitivity
and specificity of 100% and 85% for an ML above 1.5 for
progression to HGD in this cohort support its use as a risk
stratification tool in BE for progression to HGD.
The strengths of our study include a true IND cohort.
Patients’ histology from preprogression tissue was rereviewed by experts in gastrointestinal pathology. In addition patients were excluded if there were any signs of

Discussion
In this study we show that ML can help risk-stratify
patients who may progress to dysplasia in patients with BE
with IND. In this study 29% progressed to dysplasia (LGD
and HGD) and 7% progressed to HGD. This is in line
with other single-centre series from tertiary care centre.
Previous studies have shown an annual progression rate
of 12.9%–25% depending on the series.21–23 Seven out
of the eight patients who progressed to dysplasia in our
study had some level of genomic instability. ML had
been shown previously to help risk-stratify patients with
non-dysplastic BE or with LGD in regard to progression
to HGD.16 As discussed earlier, these IND patients can
be difficult to manage and require more intense surveillance. Thus further risk stratification can be helpful in
this subgroup of patients.
This study is novel in that it is the first to examine if
ML can be a predictor of progression to true dysplasia in
patients with BE and IND. Previous studies have shown
ML to be a predictor for progression in non-dysplastic
disease.18 19 Other studies have looked at DNA content

Table 3 ML performance in predicting future progression to HGD in IND patients at baseline
No IND progression IND progressed
to HGD
to HGD

% IND that progressed to
Specificity (%) Sensitivity (%) HGD

ML=0
ML=0.5–0.75

11
6

0
0

NA
42

NA
100

ML=1.0–1.25

5

0

65

100

ML=1.5–1.75

2

1

85

100

ML ≥2
Total

2
26

1
2

92

50

0% progressed
(low risk)
33% progressed (higher risk)
Overall 7% of IND progressed

HGD, high-grade dysplasia; IND, indefinite for dysplasia; ML, mutational load; NA, not available.
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oesophagitis on pathology or if patients were not optimised on a medical antacid regimen.
Our study does have limitations. This is a singlecentre, retrospective study. We decided to make this
a single-centre study to control for heterogeneity in
pathological classifications. It also afforded us the opportunity to allow our pathologists to review all baseline
pathology. In addition the sample size is relatively small
at 28 patients. Another limitation is that despite patients
undergoing standard-of-care Seattle protocol biopsies,
it is possible that LGD or HGD is missed on the initial
exam if a dysplastic area was not seen on endoscopy and
missed on random biopsies, especially since this cohort
consists of patients with long-segment Barrett’s. This is a
known phenomenon that can occur in any surveillance
programme.11 28 Finally the follow-up period that was
required for this study was only 1 year (54% of patients
had 3-year follow-up). It is possible that patients who had
ML levels above 0.5 and did not progress may progress to
low-grade or high-grade dysplasia on further follow-up.
Despite the limitations our pilot study shows that ML
may be a useful test for risk stratification in BE-IND. It
should be noted that we are not advocating ablation
based on ML levels. The decision for ablation should be
dictated by the presence of dysplasia, as per the guidelines. However we do feel that ML can dictate surveillance intervals and thus help risk-stratify patients. Larger
studies in the future on a BE-IND cohort may give more
insight into the sensitivity and specificity of the test. In
our study we had one patient with a high ML (>2) with
over 3 years of follow-up who never developed dysplasia.
On the other hand, we had a patient who developed LGD
who never had a measurable ML. Given the small cohort,
this affects the sensitivity and specificity of the test, per
table 2. Larger studies would be able to account for these
extremes and give a better estimate of the sensitivity and
specificity of ML in predicting progression to dysplasia.
Despite the small numbers it seems that the sensitivity
and specificity for development of HGD at ML of 1.5–1.75
(100, 85%) hold promise to be a possible indicator of
BE-IND to develop to HGD. Larger prospective observational studies are needed to confirm our findings given
only two patients in the cohort progressed to HGD.
In summary, IND patients had a low risk of progression to HGD but a significantly higher risk of progression to any to type of dysplasia (LGD or HGD). Genomic
instability can further refine risk in these patients by
dividing them into categories: (1) those at lower risk of
progression to dysplasia and (2) those at higher risk of
progression to dysplasia compared with the risk initially
conferred by their baseline pathology diagnosis of IND
alone. Our results are consistent with those of previous
studies demonstrating that ML can be a useful biomarker
in identifying patients with BE at risk of future progression to EA, allowing for closer surveillance or cancer
preventative treatment in patients at higher risk of
progression and avoiding unnecessary interventions in
those at lower risk.
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